# Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

> **NCT04617860** · PHASE1,PHASE2 · TERMINATED · sponsor: **Wave Life Sciences Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** WVE-120102

## Key facts

- **NCT ID:** NCT04617860
- **Lead sponsor:** Wave Life Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-24
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-04-29
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617860, "Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04617860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*